博晖创新子公司获得静注人免疫球蛋白临床试验批准

Core Viewpoint - The company announced that its subsidiary, Guangdong Weilun Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for clinical trials of intravenous immunoglobulin [1] Group 1: Company Developments - Guangdong Weilun has been granted a Clinical Trial Approval Notice for intravenous immunoglobulin, allowing it to proceed with clinical trials [1] - The intravenous immunoglobulin product is already marketed and sold both domestically and internationally [1] Group 2: Industry Context - Several blood product companies in China, including the company's subsidiary Bohui Biopharmaceutical (Hebei) Co., Ltd., Beijing Tiantan Biological Products Co., Ltd., Shandong Taibang Biological Products Co., Ltd., and Hualan Biological Engineering Co., Ltd., have intravenous immunoglobulin products available in the market [1]